
|Articles|January 1, 2004
Alcon rings NYSE bell; anecortave trials begin
New York-Tim Sear, Alcon Inc.'s chairman, president, and chief executive officer, rang the closing bell of the New York Stock Exchange at 4 p.m. Dec. 4 to celebrate the company's dramatic rise in stock price since its initial public offering.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Neurotrophic keratitis outcomes improve with early, stage-based care
3
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5












































.png)


